Ipsen Biopharmaceuticals, Inc.
1 Main Street
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
557 articles with Ipsen Biopharmaceuticals, Inc.
Ipsen announced that its Board of Directors has appointed David Loew as its new Chief Executive Officer and as Board member.
After four years as head of Sanofi’s vaccines division, David Loew is departing the pharma giant to take on a new role – chief executive officer of Paris-based Ipsen, effective July 1.
Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence
Over 400 patients with spasticity or cervical dystonia responded to online surveys evaluating the disease burden and the impact on their personal and professional lives
Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program
Ipsen, a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, announced they entered into an option agreement by which Ipsen would acquire an exclusive license for the worldwide rights to a high-value oncology program.
Continued momentum with Q1 2020 Group sales growth of 9.6% as reported, or 8.7%1 at constant exchange rates
Ipsen Announces Positive Topline Results From Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Previously Untreated Advanced Renal Cell Carcinoma
Ipsen Announces Positive Topline Results From Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX ® (cabozantinib) in Combination with Opdivo® (nivolumab) in Previously Untreated Advanced Renal Cell Carcinoma Study met primary endpoint of significantly improving progression-free survival, and secondary endpoints of overall survival and objective response rate vs. sunitinib CABOMETYX in combination with Opdivo demonstrates clinically m
The biopharmaceutical group Ipsen has answered call of the Institut Pasteur and announces a donation of €2 million dedicated to COVID-19 research.
As the biopharma industry responds to the COVID-19 pandemic, some of the area's companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here's a look.
3/30/2020Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
Ipsen to reinitiate palovarotene dosing in patients 14 years of age and older with fibrodysplasia ossificans progressiva
A partial clinical hold placed at the end of last year remains in effect and the company has opted to terminate a trial in patients with multiple osteochondromas.
Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of the Presto study by ENETS.
Ipsen Data Presented during ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs and Acromegaly
Studies include quantitative findings from patients and healthcare professionals, and new perspectives on somatostatin analogs in the management of neuroendocrine tumors (NETs) and acromegaly
Ipsen, a global specialty-driven biopharmaceutical group, today announced its financial results for the full year 2019.
Ipsen’s decision to pause dosing in its studies of palovarotene trials for patients with fibrodysplasia ossificans progressive (FOP) has hit the France-based company right in the pocketbook.
Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria
Based on encouraging therapeutic activity signals observed in preliminary post-hoc analyses and recommendations from the Independent Data Monitoring Committee, Ipsen to conduct further assessment of the complete data set and work with the regulatory authorities to determine the path forward
The company hopes to resume the trials following an assessment of data.
Ipsen announced the appointment of Dr. Steven Hildemann as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance effective March 1, 2020.
Ipsen announced that David Meek has resigned as the company’s Chief Executive Officer and will step down from the Board of Directors, effective December 31, 2019, to pursue another professional opportunity as President and Chief Executive Officer of FerGene.
FerGene launched last month with a $570 million investment from Ferring and Blackstone Life Sciences.